OssDsign Croissance future
Future contrôle des critères 2/6
OssDsign devrait augmenter ses bénéfices et son chiffre d'affaires de 35.4% et de 23.8% par an respectivement. Le BPA devrait croître de de 38.3% par an. Le rendement des capitaux propres devrait être -12.7% dans 3 ans.
Informations clés
35.4%
Taux de croissance des bénéfices
38.33%
Taux de croissance du BPA
| Medical Equipment croissance des bénéfices | 21.6% |
| Taux de croissance des recettes | 23.8% |
| Rendement futur des capitaux propres | -12.69% |
| Couverture par les analystes | Low |
| Dernière mise à jour | 06 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jun 18
OSSD: Refined Forecast Assumptions And Q1 2026 Guidance Support Upside Potential
Analysts have kept their OssDsign price target steady at SEK5.10, with only small tweaks to inputs such as discount rate, revenue growth, profit margin and future P/E, which feed into an unchanged fair value view. What’s in the News for OssDsign OssDsign issued earnings guidance for the first quarter of 2026, indicating an expected loss before interest and taxes in a range of SEK 12.0 million to SEK 14.0 million.Mise à jour du récit • Jun 04
OSSD: Refined Forecast Assumptions Will Support Future Upside Potential
Analysts have maintained their SEK fair value estimate for OssDsign while updating inputs such as revenue growth, profit margin, discount rate and a lower future P/E assumption. Together, these changes support a refined price target framework without altering the headline SEK figure.Mise à jour du récit • May 03
OSSD: Higher Long Term Margins And Moderate P/E Will Support Future Upside
Analysts have revised their price target for OssDsign to SEK 5.1 from SEK 13.5. The change reflects updated assumptions around growth, profitability and a more moderate future P/E multiple. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, indicating a loss before interest and taxes in the range of SEK 12.0 million to SEK 14.0 million, with only marginal exchange rate impact (Key Developments).
Mise à jour du récit • Apr 18
OSSD: Stable Loss Outlook And Assumptions Will Support Future Multiple Re Rating
Analysts have kept their OssDsign price target steady at SEK 12.75, indicating only marginal tweaks in the discount rate, long term revenue growth, profit margin and future P/E assumptions, rather than any major shift in their view of the company. What's in the News OssDsign issued earnings guidance for the first quarter of 2026, focusing on loss before interest and taxes rather than revenue or profit metrics.Mise à jour du récit • Apr 04
OSSD: Stable Profitability Assumptions Will Support Future Multiple Re rating
Analysts keep their SEK 12.75 price target on OssDsign unchanged, citing steady assumptions around growth, margins, and a future P/E near 113x as the basis for maintaining the current valuation. Valuation Changes Fair Value: SEK 12.75 remains unchanged, so the target valuation level is consistent with prior assumptions.Mise à jour du récit • Mar 20
OSSD: Stable Assumptions Will Support Long Term Margin Expansion
Analysts have maintained their SEK 12.75 price target for OssDsign, citing stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E as the basis for this unchanged view. Valuation Changes Fair Value: SEK 12.75 remains unchanged, signalling a stable central valuation estimate.Mise à jour du récit • Mar 05
OSSD: New US Leadership Will Support Long Term Margin Expansion
Analysts have kept their OssDsign price target steady at SEK 12.75, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for maintaining their view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew plc, Medtronic Sofamor Danek Inc, and Medacta USA (Key Developments).Mise à jour du récit • Feb 19
OSSD: New US-Focused Leadership Will Support Long Term Margin Expansion
Analysts are maintaining their SEK 12.75 price target on OssDsign. They point to a slightly higher discount rate, broadly similar revenue growth assumptions at around 26%, a lower profit margin outlook, and a higher future P/E expectation as key inputs behind this unchanged view.Mise à jour du récit • Feb 04
OSSD: US Leadership Change Will Support Long Term Margin Expansion
Analysts have reduced their price target on OssDsign to €12.75 from €15.50, citing updated assumptions for growth, margins, and a lower future P/E multiple. What's in the News OssDsign AB appointed Mark Waugh as CEO, with his tenure set to begin on January 1, 2026, following a leadership transition from current CEO Morten Henneveld (Key Developments).Mise à jour du récit • Jan 20
OSSD: New US Based Leadership Will Drive Future Orthobiologics Expansion
Analysts have kept their price target for OssDsign steady at €13.50, citing only marginal adjustments to the discount rate, revenue growth, profit margin and forward P/E assumptions that together are not enough to shift their overall valuation view. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following his senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement).Mise à jour du récit • Jan 06
OSSD: New US Focused Leadership Will Shape Bullish Future Outlook
Analysts have adjusted their price target on OssDsign to $13.50, reflecting updated assumptions around revenue growth, profit margin and a much higher implied future P/E multiple, while keeping their fair value estimate unchanged at $13.50. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, following five years of leadership under outgoing CEO Morten Henneveld (Key Developments).Mise à jour du récit • Dec 13
OSSD: New Leadership And Index Inclusion Will Shape Balanced Future Outlook
The analyst price target for OssDsign has been raised from SEK 12.0 to SEK 13.5, as analysts factor in a higher long term valuation multiple despite slightly slower projected revenue growth and a softer profit margin profile. What's in the News OssDsign AB appointed Mark Waugh as CEO, effective January 1, 2026, succeeding Morten Henneveld after five years of leading the company through growth and transformation (company announcement) New CEO Mark Waugh brings over 20 years of international leadership experience across major orthopedic segments in the USA and Europe, including senior roles at Smith & Nephew, Medtronic Sofamor Danek, and Medacta USA (company announcement) OssDsign Catalyst driven orthobiologics focus has supported strong double digit growth in the U.S. market since its launch in August 2021 (company announcement) OssDsign AB (publ) has been added to the S&P Global BMI Index, increasing its visibility to international institutional investors (index provider) Valuation Changes Fair Value: Raised from SEK 12.0 to SEK 13.5, reflecting a modest upward revision in the company’s long term valuation.Mise à jour du récit • Aug 08
Pure Play Orthobiologics Will Expand US Healthcare Access
With OssDsign's consensus price target revised lower, primarily driven by a notable drop in its Future P/E from 77.22x to 64.47x, the fair value estimate has decreased from SEK15.67 to SEK14.83. What's in the News An undisclosed buyer acquired an unknown minority stake in OssDsign AB from Karolinska Development AB.Article d’analyse • May 08
Optimistic Investors Push OssDsign AB (publ) (STO:OSSD) Shares Up 31% But Growth Is Lacking
OssDsign AB (publ) ( STO:OSSD ) shareholders would be excited to see that the share price has had a great month...
Nouveau récit • Apr 07
Pure Play Orthobiologics Will Expand US Healthcare Access
Strategic shift to orthobiologics boosts growth and operational efficiency, enhancing future revenue and sustaining high net margins.Article d’analyse • Feb 21
OssDsign AB (publ)'s (STO:OSSD) 25% Price Boost Is Out Of Tune With Revenues
OssDsign AB (publ) ( STO:OSSD ) shares have continued their recent momentum with a 25% gain in the last month alone...Article d’analyse • Feb 07
Analysts Are Upgrading OssDsign AB (publ) (STO:OSSD) After Its Latest Results
OssDsign AB (publ) ( STO:OSSD ) defied analyst predictions to release its full-year results, which were ahead of market...Article d’analyse • Nov 15
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
OssDsign AB (publ) ( STO:OSSD ) just released its latest quarterly results and things are looking bullish. OssDsign...Article d’analyse • Nov 13
OssDsign AB (publ)'s (STO:OSSD) Share Price Matching Investor Opinion
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 5.7x might make it look like a sell right now...Article d’analyse • Aug 23
OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price
Last week, you might have seen that OssDsign AB (publ) ( STO:OSSD ) released its quarterly result to the market. The...Article d’analyse • Aug 06
We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d’analyse • Jun 19
Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now
Key Insights OssDsign's Annual General Meeting to take place on 25th of June CEO Morten Henneveld's total compensation...Article d’analyse • Mar 19
Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely
OssDsign AB (publ)'s ( STO:OSSD ) price-to-sales (or "P/S") ratio of 8.5x might make it look like a strong sell right...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 308 | -14 | -37 | -27 | 3 |
| 12/31/2027 | 238 | -36 | -47 | -42 | 3 |
| 12/31/2026 | 168 | -51 | -66 | -49 | 3 |
| 3/31/2026 | 173 | -48 | -65 | -53 | N/A |
| 12/31/2025 | 180 | -51 | -71 | -64 | N/A |
| 9/30/2025 | 176 | -42 | -59 | -54 | N/A |
| 6/30/2025 | 168 | -46 | -57 | -53 | N/A |
| 3/31/2025 | 151 | -53 | -62 | -60 | N/A |
| 12/31/2024 | 134 | -50 | -63 | -62 | N/A |
| 9/30/2024 | 127 | -90 | -81 | -81 | N/A |
| 6/30/2024 | 123 | -114 | -91 | -91 | N/A |
| 3/31/2024 | 118 | -118 | -95 | -95 | N/A |
| 12/31/2023 | 112 | -130 | -94 | -94 | N/A |
| 9/30/2023 | 97 | -109 | -93 | -93 | N/A |
| 6/30/2023 | 83 | -95 | -93 | -93 | N/A |
| 3/31/2023 | 71 | -99 | -92 | -92 | N/A |
| 12/31/2022 | 57 | -99 | -86 | -86 | N/A |
| 9/30/2022 | 46 | -96 | -82 | -82 | N/A |
| 6/30/2022 | 38 | -93 | -98 | -98 | N/A |
| 3/31/2022 | 33 | -95 | -90 | -90 | N/A |
| 12/31/2021 | 32 | -94 | -90 | -90 | N/A |
| 9/30/2021 | 29 | -90 | -94 | -93 | N/A |
| 6/30/2021 | 27 | -92 | -77 | -76 | N/A |
| 3/31/2021 | 23 | -90 | -83 | -80 | N/A |
| 12/31/2020 | 25 | -85 | -82 | -79 | N/A |
| 9/30/2020 | 24 | -89 | -81 | -79 | N/A |
| 6/30/2020 | 22 | -89 | -90 | -88 | N/A |
| 3/31/2020 | 22 | -85 | -87 | -86 | N/A |
| 12/31/2019 | 18 | -84 | N/A | -87 | N/A |
| 9/30/2019 | 18 | -72 | N/A | -90 | N/A |
| 6/30/2019 | 20 | -66 | N/A | -75 | N/A |
| 3/31/2019 | 21 | -62 | N/A | -78 | N/A |
| 12/31/2018 | 21 | -56 | N/A | -66 | N/A |
| 12/31/2017 | 16 | -63 | N/A | -41 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: OSSD devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: OSSD devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: OSSD devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de OSSD ( 23.8% par an) devrait croître plus rapidement que le marché Swedish ( -0.4% par an).
Croissance élevée des revenus: Le chiffre d'affaires de OSSD ( 23.8% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: OSSD devrait être non rentable dans 3 ans.
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/01 18:45 |
| Cours de l'action en fin de journée | 2026/07/01 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
OssDsign AB (publ) est couverte par 3 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Kristofer Liljeberg-Svensson | DNB Carnegie Commissioned Research |